C4 Therapeutics (CCCC) vs Entera Bio (ENTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
C4 Therapeutics (CCCC) has outperformed Entera Bio (ENTX) over the past year, gaining 31.1% versus a gain of 6.0%. Over five years, ENTX leads with a -41.2% price change compared with -92.8% for CCCC. Entera Bio is the larger company by market cap ($462.4 million vs $388.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | ENTX |
|---|---|---|
| Share price | $3.16 | $2.66 |
| Market cap | $388.76M | $462.40M |
| 1-day change | +10.88% | +6.40% |
| YTD return | +65.45% | +37.11% |
| 1-year return | +31.12% | +5.98% |
| 5-year return | -92.80% | -41.15% |
| EPS (TTM) | $-1.01 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $4.20 |
| 52-week low | $1.69 | $0.91 |
| Distance from 52-week high | -38.88% | -36.67% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +306.96% | +266.54% |
| Average volume | 2.38M | 1.82M |
| Shares outstanding | 123.03M | 173.83M |
| Employees | 104 | 20 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CCCC has outperformed ENTX by 25.1 percentage points over the past year.
- The two companies sit in different sectors: C4 Therapeutics in Healthcare and Entera Bio in Health Care.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Healthcare · Biotechnology · 104 employees
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
CCCC vs ENTX FAQ
Which is bigger, C4 Therapeutics or Entera Bio?
Entera Bio (ENTX) is larger, with a market capitalization of $462.40M compared with $388.76M for C4 Therapeutics (CCCC).
Which stock has performed better over the past year, CCCC or ENTX?
CCCC returned +31.12% over the past 12 months, compared with +5.98% for ENTX (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Entera Bio in the same industry?
No. C4 Therapeutics is in the Healthcare sector, while Entera Bio is in Health Care.